# TABLE OF CONTENT

1. **Introduction**

1.1. Cancer

1.2. History of cancer

1.3. Causes of Cancer

1.4. Different Techniques used to Study the Process of Carcinogenesis

1.5. Breast Cancer

1.6. Categorization Basis for Breast Cancer

   1.6.1 Stage

   1.6.2 Histopathology

   1.6.3 Grade (Bloom-Richardson Grade)

   1.6.4 Receptor status

1.7 Types of Breast Cancer

   1.7.1 Noninvasive Breast Cancer

      1.7.1.1 Ductal Carcinoma *In situ* (DCIS)

      1.7.1.2 Lobular Carcinoma *In situ* (LCIS)

   1.7.2 Invasive Breast Cancer

      1.7.2.1 Invasive Ductal Carcinomas (IDC)

      1.7.2.2 Invasive Lobular Carcinoma (ILC)
1.7.3 Good Prognosis, ER Positive Tumors

1.7.3.1 Tubular Carcinoma (TC)

1.7.3.2 Invasive Cribriform Carcinoma

1.7.3.3 Pure Mucinous Carcinoma

1.7.3.4 Invasive Solid Papillary Carcinoma (SPC)

1.7.3.5 Apocrine Carcinoma

1.7.3.6 Neuroendocrine Tumors

1.7.4 Good Prognosis, ER Negative

1.7.4.1 Medullary Carcinoma

1.7.4.2 Secretory Breast Carcinoma

1.7.4.3 Adenoid Cystic Carcinoma (ACC)

1.7.4.4 Acinic Cell Carcinoma

1.7.5 Poor Prognosis, ER Positive

1.7.5.1 High-Grade Small-Cell NE Carcinoma

1.7.5.2 Invasive Micro Papillary Carcinoma

1.7.6 Poor Prognosis, ER Negative

1.7.6.1 Metaplastic Carcinoma

1.7.6.2 Lipid-Rich Carcinoma
1.7.6.3 Glycogen-Rich Clear-Cell Carcinoma

1.8 Hereditary /Familial Breast Cancer

1.9 Sporadic Breast Cancer

1.10 A Global Scenario of Breast Cancer

1.11 Worldwide Breast Cancer Mortality

1.12 Characteristics of sample population

1.13 Risk Factors responsible for Breast cancer

  1.13.1 Gender and Age

  1.13.2 Nulliparity, Breast Feeding, Hormone Levels

  1.13.3 Migration and International Variation

  1.13.4 Reproductive Factors

  1.13.5 Endogenous Hormones

  1.13.6 Oral Contraceptives

  1.13.7 Exogenous Hormones

  1.13.8 Diet

  1.13.9 Alcohol and Smoking

  1.13.10 Anthropometry

  1.13.11 Exercise

  1.13.12 Radiation

  1.13.13 Carcinogens
1.13.14 Mutagens .................................................. 22
1.13.15 Familial Risk ........................................... 23
1.13.16 High-Risk Mutations ................................ 23
1.14 Genetics of Breast Cancer .............................. 23
1.15 Metastasis ....................................................... 24
1.16 Metastasis Suppressor Genes .......................... 25
1.17 Differentiation related gene 1 (DRG1) ............. 25
1.18 Phosphatase and tensin homologue deleted from chromosome10 (PTEN) .................................................. 28
1.19 Gelsolin (GSN) .................................................. 29
1.20 Present Study .................................................... 31

2 Material and Methods ....................................... 33

2.1 Materials ......................................................... 34

2.1.1 General Chemicals ......................................... 34

2.1.2 General Solutions .......................................... 35

2.2 Patients Identification and Collection of Samples .... 40

2.3 Isolation and Quantification of DNA .................. 40

2.3.1 DNA Extraction ............................................ 40

2.3.2 Quantification .............................................. 41

2.3.2.1 Spectrophotometry .................................... 41
2.3.2.2 Yield Gel Electrophoresis

2.4 Polymerase Chain Reaction (PCR)

2.4.1 Designing of Primers

2.4.2 Optimization of Amplified Products

2.4.3 Amplification of breast cancer samples and controls

2.5 Post-amplification Horizontal Agarose Gel Electrophoresis

2.6 Single Stranded Conformation Polymorphism

2.6.1 Polyacrylamide gel

2.6.2 Sample Preparation for SSCP

2.6.3 Electrophoresis

2.6.4 Staining SSCP gels with Ethidium Bromide

2.6.5 Identification of Variants and Sequencing

2.6.6 Software Application for Mutational analysis

2.7 Expression Analysis of Genes

2.7.1 RNA Extraction for Expression Analysis

2.7.2 Quantification of Extracted RNA

2.7.2.1 Spectrophotometry

2.7.3 Reverse Transcription-Polymerase Chain Reaction and cDNA Synthesis

2.7.4 Quantitative Polymerase Chain reaction (qPCR)
2.7.4.1 Primer Designing

2.7.4.2 Real Time PCR (qPCR)

2.8 Breast Cancer Cell Lines

2.8.1 MDA-MB-231

2.8.2 MCF-7

2.9 Media and Cancer Cell Lines Storage Conditions

2.9.1 Revival of Cells from Liquid Nitrogen Tanks

2.9.2 Replenishment of Medium for Breast Cancer Cell Lines

2.10 Detachment of Adherent Cells and Cell Counting

2.11 Storage of Cell Stocks in Liquid Nitrogen

2.12 Maintenance of Cancer Cell Lines

2.13 In vitro Analysis of DRG1 Molecule on Breast Cancer Cell Lines

2.13.1 Initial Screening of Breast Cancer Cell Lines

2.13.2 Designing and Generation of DRG1 ribozymes

2.13.3 Transformation of Ribozymes in Competent Cells

2.14 Selection and Orientation Analysis of Positive Colonies

2.15 Plasmid Isolation and Quantification

2.16 Transformation of Mammalian Cells using Electroporation

2.17 Establishment of Stable MDA-MB-231 and MCF-7 Cancer Cell Lines
2.18 Confirmation of Transformation

2.18.1 RNA Isolation and Expressional Analysis

2.18.2 SDS-PAGE and Western Blotting

2.19 In Vitro Characterization of DRG1 in Breast Cancer Cell Lines

2.19.1 Breast Cancer Cell Growth Assay

2.19.2 In vitro Tumor Cell Matrigel Invasion Assay

2.19.3 In vitro Tumor Cell Matrigel Adhesion Assay

2.19.4 Electric Cell-Substrate Impedance Sensing Analysis of Breast Cancer Cell Lines Migration

2.19.5 Screening of Different Molecules

2.20 Statistical Analysis

3 Results

3.1 Samples Outline of Cohort 1 in Pakistani Population

3.2 DNA Extraction

3.3 Optimization of Primers
3.4 Mutation Detection By using SSCP and Sequencing
3.5 Mutation Detection in DRG1 Gene
3.6 Sequencing of the Suspected Samples of DRG1
   3.6.1 Non-synonymous Substitution Mutation
   3.6.2 Frame Shift Mutations
3.7 Mutation Detection in PTEN Gene
3.8 Sequencing of the Suspected Samples of PTEN
   3.8.1 Synonymous Substitution (Silent)
   3.8.2 Non-synonymous Substitution
   3.8.3 Frame Shift Mutations
   3.8.4 Splice Site Variations
3.9 Mutation Detection in Gelsolin Gene
3.10 Sequencing of the Suspected Samples of Gelsolin
   3.10.1 Non-synonymous Substitutions
   3.10.2 Frameshift Mutations
   3.10.3 Synonymous Substitution
3.11 Samples Outline of Cohort 2 in Pakistani Population
3.12 DRG1 mRNA Levels in Breast Cancer Patients

3.13 PTEN mRNA Levels In Breast Cancer Patients

3.14 Gelsolin mRNA Levels In Breast Cancer Patients

3.15 Samples Outline of Cohort 3 in British Population

3.16 DRG1 mRNA Levels in Breast Cancer Patients (Cohort 3)

3.17 PTEN mRNA Levels in Breast Cancer Patients (Cohort 3)

3.18 Gelsolin mRNA Levels in Breast Cancer Patients (Cohort 3)

3.19 In vitro Studies

3.20 Expression of DRG1 in Cancer Cell Lines

3.21 Successful Generation and Transformation of DRG1 Molecule

3.22 Generation of Transformed Breast Cancer Cell Lines

3.22.1 Confirmation of DRG1 Knockdown at Transcript Level

3.22.2 Confirmation at Translation Level for DRG1

3.23 In vitro Characterization of DRG1 in Breast Cancer Cell Lines

3.23.1 Effect of DRG1 Knockdown on the Growth of Breast Cancer Cells

3.23.2 Effect of DRG1 Knockdown on Invasion of Breast Cancer Cells
3.23.3 Effect of DRG1 Knockdown on Adhesion of Breast Cancer Cells 133

3.23.4 Effect of DRG1 Knockdown on Migrational Rates of Breast Cancer Cells 136

3.24 Association of DRG1 with Different Molecules 138

4 Discussion 141

4.1 DRG1 146

4.2 PTEN 148

4.3 Gelsolin 152

4.4 In vitro Characterization of DRG1 154

5 References 158
Annexure I 184